Core Viewpoint - The company has received approval from the National Medical Products Administration for its newly developed drug, Sacubitril/Valsartan Calcium Tablets (Xinchao Tuo), which is indicated for primary hypertension and represents a significant advancement in the ARNI class of medications [1] Group 1: Drug Approval and Characteristics - The drug is the first original research product in China and the second globally approved ARNI medication, with a compound patent protection period extending until 2037 [1] - Phase III clinical trial results indicate significant antihypertensive efficacy with a clear dose-dependent response [1] Group 2: Strategic Positioning - Following the launch of Xinchao Tuo, the company will enhance its competitive position in the cardiovascular chronic disease treatment sector by complementing its existing products, Xintan and Fulitan, to meet a broader range of clinical needs [1]